Tag: TDS PDT TRI

BrightGene Presents Positive Phase 2 Data for Dual GLP-1R/GIPR Agonist for Weight Management and Type 2 Diabetes and Preclinical Data for Novel Amylin Analog...

Phase 2 data highlights best-in-class potential of dual GLP-1R/GIPR agonist BGM0504 for weight management and metabolic risk reduction in individuals with type 2 diabetes...

BrightGene Presents Positive Phase 2 Data for Dual GLP-1R/GIPR Agonist for Weight Management and Type 2 Diabetes and Preclinical Data for Novel Amylin Analog...

Phase 2 data highlights best-in-class potential of dual GLP-1R/GIPR agonist BGM0504 for weight management and metabolic risk reduction in individuals with type 2 diabetes...

Okomera Opens Pre-orders for Ocentra, the Central Engine for Automated Organoid Screening

PARIS, June 9, 2025 /PRNewswire/ -- Okomera, a biotech pioneering automated organoid-based drug discovery, today opened pre-orders for its first commercial system, Ocentra, unveiled live...

- A word from our sponsors -

Newsletter Signup

Name(Required)

First Last

Email(Required)

Enter Email Confirm Email

CAPTCHA

Privacy(Required)

I agree with the storage and handling of my data by this website. - Privacy Policy *

This field is for validation purposes and should be left unchanged.

HomeTagsTDS PDT TRI

Queen Máxima of the Netherlands Appointed Chair of Global Finance & Technology Network’s International Advisory Board

Record date for reverse share split in Fingerprint Cards AB (publ)

Transaction in Own Shares

Tag: TDS PDT TRI

BrightGene Presents Positive Phase 2 Data for Dual GLP-1R/GIPR Agonist for Weight Management and Type 2 Diabetes and Preclinical Data for Novel Amylin Analog...

BrightGene Presents Positive Phase 2 Data for Dual GLP-1R/GIPR Agonist for Weight Management and Type 2 Diabetes and Preclinical Data for Novel Amylin Analog...

Okomera Opens Pre-orders for Ocentra, the Central Engine for Automated Organoid Screening

Newsletter Signup

Explore

Press Releases

News & Opinion

Living

Others

Follow us